

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-37. (Canceled)
38. (Previously presented) A method for treating cancer, said method comprising administering to a subject in need thereof an effective amount of a nucleic acid molecule comprising a nucleotide sequence encoding IL-12 and an effective amount of 4-1BB ligand.
- 39-41. (Canceled)
42. (Previously presented) The method of claim 38, wherein the nucleotide sequence encoding IL-12 is regulated by a constitutive, inducible or tissue-specific promoter.
- 43-45. (Canceled)
46. (Previously presented) The method of claim 42, wherein the nucleic acid molecule is contained in an expression vector.
47. (Canceled)
48. (Previously presented) The method of claim 42, wherein the nucleic acid molecule is contained in a viral vector.
49. (Canceled)
50. (Previously presented) The method of claim 48, wherein the viral vector is an adenovirus vector.
51. (Canceled)
52. (Previously presented) The method of claim 48, wherein the viral vector is a retroviral vector or an adeno-associated viral vector.
53. (Canceled)
54. (Previously presented) The method of claim 38, wherein the nucleotide sequence encodes human IL-12.
55. (Canceled)
56. (Currently amended) The method of claim 38 or 54, wherein the 4-1BB ligand is human 4-1BB ligand.
57. (Canceled)

58. (Previously presented) The method claim 38, wherein the subject is a non-human mammal.
59. (Canceled)
60. (Currently amended) The method of claim 38 or 54, wherein the subject is a human.
61. (Canceled)
62. (Previously presented) The method of claim 38, wherein the cancer is a melanoma, neoplasm, tumor or metastasis.
63. (Canceled)
64. (Previously presented) The method of claim 38, wherein the cancer is colon cancer, colorectal cancer, melanoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, lung cancer or hepatic cancer.
65. (Canceled)
66. (Previously presented) The method of claim 38, wherein the nucleic acid molecule is administered intratumorally.
67. (Canceled)
68. (Previously presented) The method of claim 38, wherein the nucleic acid molecule is administered intradermally, intramuscularly, subcutaneously, intraperitoneally, intravenously or orally.
69. (Canceled)
70. (Previously presented) The method of claim 38, wherein the 4-1BB ligand is administered intratumorally, intradermally, intramuscularly, subcutaneously, intraperitoneally, intravenously or orally.
- 71-75. (Canceled)
76. (New) The method of claim 50, wherein the nucleotide sequence encodes human IL-12.
77. (New) The method of claim 50 or 76, wherein the 4-1BB ligand is human 4-1BB ligand.

78. (New) The method of claim 50, wherein the subject is a non-human mammal.
79. (New) The method of claim 56, wherein the subject is a human.
80. (New) The method of claim 50 or 76, wherein the subject is a human.
81. (New) The method of claim 77, wherein the subject is a human.
82. (New) The method of claim 50, wherein the adenovirus is administered intratumorally.
83. (New) The method of claim 50, wherein the adenovirus is administered intranasally.